Metabolic syndrome in association with novel dietary index, metabolic parameters, nesfatin-1 and omentin-1
BMC Endocrine Disorders · 2024
DOI: 10.1186/s12902-024-01791-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Endocrine Disorders, 2024. Verfasst von Houshang Bavandpour Karvane und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Metabolic Syndrome, Nucleobindins, GPI-Linked Proteins, Cytokines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Metabolic syndrome is a prevalent and common health problem and numerous studies have revealed the role of diet and lifestyle change in prevention of metabolic syndrome. However, the novel dietary index, cardioprotective index (CPI) and its association with metabolic syndrome is not investigated yet. In the current study, we evaluated the association between metabolic syndrome and its components, CPI, Nesfatin-1 and Omentin-1in a cross-sectional study. METHODS: Three hundred forty eight overweight and obese individuals with metabolic syndrome were recruited. Subjects underwent anthropometric and laboratory assays including metabolic markers, Nesfatin-1 and Omentin-1 with commercial kits. RESULTS: Those at the first tertile of CPI had lower high density lipoprotein concentrations (HDL) and higher low density lipoprotein concentrations (LDL), triglyceride (TG), systolic and diastolic blood pressures (SBP, DBP) levels compared with those at the highest tertiles (P 0.05). Additionally, being at the third tertile of CPI was accompanied with significantly higher Nesfatin-1 and Omentin-1 levels compared with lowest tertiels (P < 0.05) in crude and confounder - adjusted models. CONCLUSIONS: To our findings, CPI was in positive relationship with metabolic parameters, blood pressure, Nesfatin-1 and Omentin-1 levels in metabolic syndrome. Further future studies will help to elaborate the causality. CLINICAL TRIAL NUMBER: Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
- Cardiology Department, Shiraz University of Medical Science of Iran, Shiraz, Iran.
- College of Pharmacy, Alnoor University, Nineveh, Iraq.
- College of MLT, Ahl Al Bayt University, Karbala, Iraq.
- Gilgamesh Ahliya University, Baghdad, Iraq.
- Collage of Nursing, National University of Science and Technology, Dhi Qar, 64001, Iraq.
Zitieren
APA
Karvane, H. B., Esfandiari, H., Qutaiba, O., Allela, B., Mahdi, M. S., Al-Nuaimi, A. M. A., Al-Hussein, R. K. A., Jawad, M. J., Ghayourvahdat, A., & Keshavarzian, A. (2024). Metabolic syndrome in association with novel dietary index, metabolic parameters, nesfatin-1 and omentin-1. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-024-01791-2
Vancouver
Karvane HB, Esfandiari H, Qutaiba O, Allela B, Mahdi MS, Al-Nuaimi AMA, et al. Metabolic syndrome in association with novel dietary index, metabolic parameters, nesfatin-1 and omentin-1. BMC Endocrine Disorders. 2024. doi:10.1186/s12902-024-01791-2
BibTeX
@article{Karvane2024,
author = {Karvane, Houshang Bavandpour and Esfandiari, Haleh and Qutaiba, Omer and Allela, B and Mahdi, Morug Salih and Al-Nuaimi, Ali M Ali and Al-Hussein, Rouaida Kadhim A and Jawad, Mahmood Jasem and Ghayourvahdat, Arman and Keshavarzian, Ali},
title = {Metabolic syndrome in association with novel dietary index, metabolic parameters, nesfatin-1 and omentin-1},
journal = {BMC Endocrine Disorders},
year = {2024},
doi = {10.1186/s12902-024-01791-2}
}
EUVIMED